High-affinity soluble TCRs: discovery and engineering via yeast-based platform
Join Dr. Garrett Rappazzo (Adimab) in this webinar as he presents the development of soluble T cell receptors using a high-throughput yeast-based platform, enabling potent and specific peptide-HLA targeting therapeutics.
Online
Dr. Garrett Rappazzo, Senior Scientist of Platform Technologies at Adimab, will present his team’s research on the discovery and engineering of soluble T cell receptors (TCRs) for use in peptide-HLA (pHLA)-targeting therapeutics. These therapeutics offer the potential for highly specific and effective destruction of diseased and infected cells. However, natural TCRs face significant challenges, such as the need for extensive affinity enhancement and immune tolerance mechanisms that limit discovery.
To overcome these hurdles, Adimab developed the first fully human synthetic TCR libraries using a yeast-based platform. This approach enabled the rapid identification of diverse, high-affinity TCRs and the engineering of TCR variants with improved affinity and functionality, while maintaining precise specificity for pHLA targets.
- Speaker: Dr. Garrett Rappazzo, Senior Scientist, Platform Technologies, Adimab
- Organizer: KACTUS
KACTUS’ webinar will cover novel technologies for the discovery and optimisation of soluble TCRs, and how these molecules can be characterised for both affinity and specificity supporting the development of potent and specific pHLA-targeting therapeutics for diverse cancers and viral diseases.